Abstract: Biliary tract cancers (BTC)/Cholangiocarcinoma (CCA) is an aggressive biliary tract epithelial malignancy from varying locations within the biliary tree with cholangiocyte depreciation., including intrahepatic cholangiocarcinoma (iCCA) (iCCA), extrahepatic cholangiocarcinoma (eCCA) and gallbladder carcinoma (GBC). The disease is largely heterogeneous in etiology, epidemiology, and molecular profile.
Introduction
Biliary tract cancers (BTC)/Cholangiocarcinoma (CCA) are resulting from malignant transformation of epithelial cells within the bile system as related but distinct malignancies along the intrahepatic and extrahepatic biliary tree. Besides the gallbladder carcinoma (GBC), CCA is also refers to cancers of the entire biliary tree. CCA is commonly classified as intrahepatic cholangiocarcinoma (iCCA) and extrahepatic cholangiocarcinoma (eCCA), with extrahepatic further divided into perihilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA) tumors based on anatomical location with the cystic duct as the point of distinction (1) . There is increasing recognition that these subtypes separated by anatomic origins of BTCs distinct not only in desmoplasia markers of cholangiocytes, but also in biological and clinical characteristics (2) . BTC has an aggressive natural course without early specific warning sign of the disease; therefore, potential curative surgery is only suitable for a limited number of patients. So far, systemic treatment is confined to the gemcitabine and cisplatin combination as the practice standard for patients with advanced and metastatic disease (3) . The overall outcome is disappointing with limited response rate (RR) and low 5-year survival rate. It is crucial to understand BTC/CCA carcinogenesis, tumor-stroma interactions, and key molecular pathways, and herald to establish targeted, individualized therapies for the heterogeneous disease, and eventually to improve the survival and overall outcomes of patients. In this review, we are going to summarize the
Review Article
Targeted therapy in biliary tract cancers-current limitations and potentials in the future results of systemic cytotoxic chemotherapy, and review the data from studies with 'target-oriented' agents. Since most of these studies are not targeting the distinguished subgroups of the disease specifically, they are more likely as 'target intended' rather than 'target-oriented'. We will also discuss the current knowledge regarding the genetic basis of this disease, including molecular pathways involved in its carcinogenesis, and potential targeted therapies that hold promise in the future research and practice.
Cytotoxic chemotherapy
Cytotoxic chemotherapy remains the mainstay of treatment for patients with advanced unresectable or metastatic BTC. Given the rarity of this disease, clinical studies have been small and have almost always been combined with 'lumping' various BTCs with very few randomized trials have been conducted. The majority of trials have been performed with either fluoropyrimidine-based or gemcitabine-based combination. 5-flourouracil (5-FU) had been tested in small trials, both as monotherapy and in combinations. Overall RRs in these studies varied from 10% to 40%; median survival also varied notably, from 5 to 16 months (4-21).
A phase III study randomized 54 patients with previously untreated advanced biliary cancer between ECF (epirubicin, cisplatin, 5-FU) and FELV (5-FU/LV, etoposide) (14) . The median OS was not significantly different between the two arm (9.02 months in ECF vs. 12.03 months in FELV, P=0.2059). Objective RRs were also similar (19.2% in ECF vs. 15% in FELV, P=0.72). The interesting point is greater than 60% of patients in each arm demonstrated resolution of pain, anorexia, weight loss, and nausea.
Based on the data of studies from advanced and metastatic pancreatic cancer, gemcitabine has also been evaluated biliary cancers at the similar setting (7, 12, 15, 16, (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (Table 1) . As a single agent, gemcitabine showed only moderate efficacy with RRs ranging from 0% to 30% at varied dosing schemes demonstrated. Efforts had been tried in combination of gemcitabine with multiple other cytotoxic agents, including 5-FU, capecitabine, cisplatin, oxaliplatin, and irinotecan with significant variations in RRs and survival.
In order to assess the overall efficacy of systematic chemotherapy, a pooled analysis was performed including 104 trials published between 1985 and 2006 (42 
Target intended therapy
Although the combination of gemcitabine and cisplatin has achieved some advances in the treatment of advanced and metastatic biliary track cancers and has been accepted as the standard treatment option as the first line therapy since 2010, the overall outcome is still disappointing. Clinic studies of target-oriented agents (most of them in combination with gemcitabine based regimen) have been attempted for improving the outcomes of the disease. Those target-oriented agents primarily are monoclonal antibodies and tyrosine kinase inhibitors against EGFR and vascular endothelial growth factor (VEGF) (43-57) ( , gallbladder cancer patients only. RR, response rate; mPFS, median progression-free survival; mOS, median overall survival; Gem, gemcitabine; NR, not reported; 5-FU, 5-fluorouracil; LV, leucovorin; MMC, mitomycin-C; Cis, cisplatin; Cape, capecitabine; Ox, oxaliplatin; Pem, pemetrexed; BTC, biliary tract cancers; CCA, cholangiocarcinoma. metastatic biliary tract adenocarcinoma to the combination of gemcitabine and oxaliplatin (GemOx) with erlotinib or chemotherapy (GemOx) alone (49) . The combination showed increased RR (30% vs. 16%, P=0.005), however, there were no significant difference in mPFS (5.8 vs. 4.2 months, P=0.087) and median overall survival (mOS) (9.5 months for both arms). A randomized phase II study evaluated the GemOx with or without cetuximab in 150 patients with advanced and metastatic BTC (51) . There were no differences between the two arms in RR, mPFS or mOS.
The TCOG trial evaluated the same regimen in advanced and metastatic BTC patients with stratification of iCCA/ eCCA/GBC (71.3%/16.4%/12.3%) and KRAS status (36.1% KRAS mutation). On the intent-to-treat analysis, it showed some benefit of mPFS in the arm of GemOX + cetaximab (7.1 vs. 4.0 months, P=0.0069), but no difference in RR (27.3% vs. 15%, P=0.1223), and mOS (10.3 vs. 8.8 months, P=0.4057). Planned subgroup analysis showed that potential more benefits of cetaximab with GemOX in KRAS mutated patients with mPFS of 7.1 vs. 1.9 months (P=0.0351), however, no statistical significance in mOS (10.3 vs. 6.6 months, P=0.6924) (58) . Interestingly, a pooled analysis with 161 trials comprising 6,337 patients (trials published in English between 1/2000 and 1/2014 as well as ASCO abstracts 2010 to 2013) showed some potential survival benefits of gemcitabine-based chemotherapy with targeted therapy (predominantly EGFR inhibitor as either monoclonal antibody or TKI) (59). 
New insights into the molecular pathogenesis and therapeutic opportunities
Recent studies have begun to uncover the genetic and molecular processes underlying carcinogenesis using advanced technologies such as next-generation sequencing (NGS) in the BTC. The emerging knowledge and data generated from studies of epidemiology, genome profiling , and laboratory based investigations provide new insights into risk factors, genomic composition, cellular origins and contribution of the tumor microenvironment to the pathogenesis of BTC. The remarkable genetic heterogeneity of BTC may be the result of a complex interplay among different factors-some of them are shared by most human cancers, while others may be unique for this malignancy. Emerging data supports that iCCA, eCCA, and GBC represent distinct tumors arising from different genetic backgrounds (60, 61) .
Cancer-associated fibroblasts (CAF) in the tumor stroma
CAF secondary to desmoplastic response is a prominent tumor microenvironment characteristics of biliary track cancers, especially iCCA. CAF may impede access of therapeutic agents to the tumor and pose therapeutic challenges further besides the genetic heterogeneity of this malignancy (1, 62) . Preclinical studies have demonstrated a reduction in fibrosis and carcinogenesis in BTC/CCA with 1D11, a transforming growth factor β (TGF-β) antagonist, as well as curcumin, a nutraceutical agent (63) . A pre-clinic study with an orthotopic CCA model showed that the BH3 (BCL-2 family protein, pro-apoptosis) mimetic, Navitoclax, enhanced selective CAF apoptosis, decreased expression of α-SMA, and reduced tumor burden and metastasis while improving survival (64) . Further preclinical and clinical studies are needed to explore the role of antifibrotic therapies in CCA chemoprevention.
Inflammation and carcinogenesis
Chronic inflammation plays a significant role in the development of BTC. Chronic inflammatory pathways not only are key components in carcinogenesis, but also promote tumor invasion and migration. Primary sclerosing cholangitis (PSC), hepatobiliary flukes Opisthorchis viverrini (O. viverrini) and Clonorchis sinensis characterized by chronic biliary tract inflammation and liver injury, are common predisposing conditions for BTC. In addition, prolonged hepatolithiasis may promote CCA development by calculi occurring proximal to the hepatic duct confluence (2, 65) . Inducible nitric oxide synthase (iNOS) activation by inflammatory cytokines contributes to nitrosative stress by generation of excess nitric oxide, which then results in inhibition of DNA repair proteins, and single-stranded, double-stranded, and oxidative DNA lesions. Oxidative stress via generation of oxysterols, cholesterol oxidation products present in human bile, creates a milieu favorable for tumor development and progression by activating Hedgehog signaling pathway. Oxysterols, bile acids, and iNOS all stimulate over-expression of cyclooxygenase-2, which has been implicated carcinogenesis of BTC (66) (67) (68) . Therefore, inflammatory processing control may play a significant role in management of BTC, especially in the prevention.
Genomic profiling studies
Genomic profiling has demonstrated characteristic profiles for iCCA and eCCA. Next generation sequencing (NGS) of a BTC series showed key variations in certain mutations based on tumor location (69) . Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) genes have consistently been shown to be more frequent in iCCA versus eCCA or GBC. IDH mutations caused inhibition of HNF-4α (hepatocyte nuclear factor 4 alpha, a nuclear receptor; also known as NR2A1-nuclear receptor subfamily 2, group A, member 1), leading to impaired hepatocyte differentiation and increased cell proliferation, and associated with poorly differentiated histology. FGFR (Fibroblast growth factor receptor) mutations, specifically in FGFR2 are associated with the production of two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1 that are mutually exclusive with KRAS/BRAF mutations. The median cancer specific survival is suggested significantly longer for patients whose tumors contained FGFR2 translocations (70 Activating mutations in cell proliferation oncogenes lead to uncontrolled cell growth and survival. The Ras/ MAPK signaling pathway plays a key role in cell growth, differentiation, survival, and migration. Gain-of-function mutations in KRAS are present in approximately 45-55% of iCCA and 10-15% of eCCA. One study showed that BRAF, an important downstream effector of KRAS, was found to be mutated in 22% of iCCA, no BRAF mutation was found in those cases with KRAS mutations; however, KRAS mutations were seen in 20% of tumors with BRAF mutations (72) . The ErbB family consists of four receptor kinases, including ErbB1 (or EGFR) and ErbB2 [or human epidermal growth factor receptor 2 (HER2)]. Mutations in the EGFR gene were seen in 15% of CCA cases (73) . MET is an oncogene that encodes for the hepatocyte growth factor (HGF) receptor. HGF/MET pathway is less established but may be important in development and progression of BTC/CCA. MET is a key regulator of invasive growth. Interaction of HGF and its receptor MET can activate many pathways including MAPK, PI3K and STAT. Overexpression of MET occurs in 12-58% of cases of iCCA and has been linked to overexpression of members of the EGFR family and shown the capacity of HGF to stimulate migration and invasion in CC cells (74) .
Loss-of-function mutations in tumor suppressor genes also play a role in CCA. CDKN2A (p16INK4a) negatively regulates proliferation in normal cells and is capable of cell cycle arrest. This tumor suppressor gene was highly mutated in reports with 55% loss-of-function in iCCA and 83% in eCCA. TP53, a principal regulator of cell division, appears to be inactivated in approximately one-third of BTC, both iCCA and eCCA. SMAD4, in conjunction with the other SMAD proteins, is an end effector in the TGFβ pathway with promotes epithelial-mesenchymal transition, directly regulating the activity of genes controlling cell proliferation. Mutations in SMAD4 were described in up to 40% in iCCA with the relationship of disease staging (75) . A recent large cohort study with 103 iCCA in identification of an iCCAspecific mutation signature that is associated with liver inflammation, fibrosis and cirrhosis (76) . The study found that TP53-defection is more likely to be HBsAg-seropositive, whereas KRAS mutations are nearly exclusively in HBsAgseronegative CCA patients. The study demonstrated that three pathways (Ras/PI3K, p53/cell cycle, and TGFβ/Smad), genes important for epigenetic regulations and oxidative phosphorylation are substantially affected in iCCA.
Potential role of stem and progenitor cells
Besides the different carcinogenetic mechanisms driven by risk factors in BTC, the distinct genetic profiles are also reflecting two distinct stem cell niches, the canals of Hering harboring hepatic stem cells (HpSCs) and the peribiliary glands harboring biliary tree stem/progenitor cells (BTSCs) (77) . Cell populations from HpSCs and BTSCs lineages may represent distinct candidate cells of origin during CC carcinogenesis, susceptible to distinct risk factors and responsible for the development of the different iCCA and eCCA or GBC subtypes: e.g., BTSC lineage may be activated under pathological conditions affecting the large intrahepatic and extrahepatic bile ducts (including liver flukes, cholangitis, PSC, hepatolithiasis, etc.), giving rise to large bile duct pure mucin secreting iCCA and eCCA; conversely, the hHpSC lineage has been suggested to be activated in response to parenchymal liver diseases (such as chronic viral/non-viral liver disease, schistosomiasis and liver cirrhosis) and to be involved in the development of combined hepatocellular carcinomaiCCA, bile ductular iCCA and mixed iCC A (with a focal hepatocytic differentiation, ductular reaction and mucinsecreting adenocarcinoma). This stem cell compartment is probably activated also during nonalcoholic steatohepatitis (NASH) and asbestos exposure, as these two risk factors are exclusively associated with the development of ICC.
Summary and future directions
Despite some advances in treatment of BTCs, the overall outcomes of the disease remain poor. With learning from 'target intended' studies and emerging understanding of the heterogeneity and the molecular landscape of BTC, future target oriented research/studies should be based on the underlining etiology, the specific genetic profile of each subgroup, and cancer-stroma microenvironment of the selected particular disease population. A recent retrospective study showed the promising therapy with blockage of Her-2/ neu in BTC (with both GBC and CCA) patients who with the gene amplification (78) . Advances in immunotherapy may also provide new opportunities for treating BTC (79) . A complete response (CR) was reported in a chemotherapy refractory metastatic iCCA patient with mismatch-repair deficiency (dMMR) after being treated with PD-1 inhibitor (80). Most current on-going 'target-oriented' studies are less distinctive regarding the specificity of the characteristic mechanism of the disease (Tables 3,4) . However, we are certain that the future studies will be more precisely to meet our goal. BTC, biliary tract cancers; DC-PNAT, dendritic cell-precision T cell for neo-antigen.
